Good news in the fight against Covid… After Moderna Therapeutics – announcing on Monday November 30 they applied for approval to issue their vaccine in Europe and the United-States of America – this is now Pfizer/BioNTech that are seeking approval in Europe, the day after, naming Tuesday December 1. The company applied for Conditional Marketing Authorization (CMA) the day before, as announced by BioNTech this Tuesday and the company already applied for emergency use back to November 20 in the United States, to the FDA, the Food & Drug Administration.
As for the European Medicines Agency (EMA), they said this Tuesday December 1, they will examine the application by December 29 during a special meeting scheduled on that date “at the latest” to approve the application or not. If the EMA concludes that the benefits of the Pfizer-BioNTech shot outweigh the risks, it will recommend granting a conditional clearance that could enable the shot to be rolled out in Europe before the end of the year.
For the record, the vaccine developed by Pfizer/BioNTech delivered more than satisfactory results as for phase 3 of the clinical trials: it is said to be 95% effective. This is the second vaccine to have applied for authorization to be issued on the European market.
